COVID-19 Treatments in the Outpatient Setting

This webinar will be presented by:

Dr. Peter Phillips
Clinical Professor
Division of Infectious Diseases, University of British Columbia

Dr. Junine Toy, PharmD
Senior Manager for the Drug Treatment Program
BC Centre for Excellence in HIV/AIDS

On completion of this webinar, attendees will be able to:

  1. Describe the currently available treatment options for patients with mild-moderate COVID-19 in the outpatient setting
  2. Identify those patients with COVID-19 infection who are high priority for receiving treatment based upon their risk of hospitalization or death
  3. Summarize the precautions, and contraindications for COVID-19 treatments
  4. Recognize and be aware of drug interactions associated with paxlovidTM (nirmatrelvir/ritonavir), including its use in people living with HIV (PLWH)
  5. Describe the practical aspects of accessing COVID-19 treatments for outpatients

Cost: Free registration.

Please register for the webinar by clicking the following link:

click here.

Presentations will be followed by a discussion where participants will have the opportunity to ask questions and receive real-time responses from presenters.

This event is accredited by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credit.

Please note the session will be recorded and available after the event on the BC-CfE’s website at education.bccfe.ca/webinars

If you have any questions regarding this event, please contact BC-CfE’s Education and Training team at: education@bccfe.ca.

Event Details

Days
Hours
Minutes
Seconds
Start Date
End Date
Event Category
Attendees of the BC-CfE Learning Series will be able to:
  • Summarize and describe epidemiological, behavioural, virological, and other related research relevant to the management of people living with HIV and other syndemic conditions
  • Describe and demonstrate up-to-date information regarding the care of people living with HIV and syndemic conditions (including viral hepatitis and substance use) particularly in regards to primary care, antiretroviral therapy and other treatments, and comorbid conditions
  • Review new and emerging issues in the context of the management of people living with HIV and other syndemic conditions
  • Identify both clinical and community resources to support the care of people living with HIV and syndemic conditions.
Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025